Home > Insider Trading > Filing (0001415889-15-000153)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1070494	Acadia Pharmaceuticals Inc	ACAD	Pharmaceutical Preparations (2834)	061376651

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1291881	Torsten Rasmussen	11085 Torreyana Road #100 San Diego CA 92121		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-01-13	4,685	$15.02	13,185	No	4	M	Indirect	See footnote
Common Stock	Acquisiton	2015-01-13	7,220	$8.49	20,405	No	4	M	Indirect	See footnote
Common Stock	Disposition	2015-01-13	11,905	$35.00	8,500	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	See footnote
No	4	M	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock option (right to buy)	Disposition	2015-01-13	4,685	$0.00	4,685	$15.02
Common Stock	Stock option (right to buy)	Disposition	2015-01-13	7,220	$0.00	7,220	$8.49

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2017-06-14	No	4	M	Indirect
2,780		2018-06-12	No	4	M	Indirect

Footnotes

Shares and options are held by Morgan Management Aps, a Danish corporation in which Mr. Rasmussen has a controlling interest.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2014.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.01 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 15, 2007.
25% of the share subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2008.